US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NervGen Pharma Corp.

4.20

+0.05001.20%

Volume:64.73K

Turnover:273.97K

Market Cap:329.05M

PE:-15.35

High:4.30

Open:4.11

Low:4.11

Close:4.15

52wk High:5.10

52wk Low:1.50

Shares:78.34M

Float Shares:78.34M

Volume Ratio:0.19

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2737

EPS(LYR):-0.2734

ROE:-820.11%

ROA:-88.77%

PB:-154.68

PE(LYR):-15.36

Loading ...

Overview Company News Filings

Company Profile

Company Name:

NervGen Pharma Corp.

Exchange:

OTCQB

Establishment Date:

2017

Employees:

- -

Office Location:

112-970 Burrard Street,Unit 1290,Vancouver,British Columbia,Canada

Website:

https://www.nervgen.com

Zip Code:

V6Z 2R4

Phone:

Fax:

- -

Introduction:

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NGENF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NGENF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGENF\",,,,,undefined,":{"symbol":"NGENF","market":"US","secType":"STK","nameCN":"NervGen Pharma Corp.","latestPrice":4.2,"timestamp":1764968400000,"preClose":4.15,"halted":0,"volume":64725,"delay":15,"floatShares":78344500,"shares":78344500,"eps":-0.273692,"marketStatus":"Market Closed","change":0.05,"latestTime":"12-05 16:00:00 EST Delay","open":4.11,"high":4.3,"low":4.11,"amount":273969.0697,"amplitude":0.045783,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.273692,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":4.15,"volumeRatio":0.18985537269752883},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGENF\",,,,,undefined,":{"symbol":"NGENF","floatShares":78344500,"roa":"-88.77%","roe":"-820.11%","lyrEps":-0.273387,"volumeRatio":0.18985537269752883,"shares":78344500,"dividePrice":0,"high":4.3,"amplitude":0.045783,"preClose":4.15,"low":4.11,"week52Low":1.5,"pbRate":"-154.68","week52High":5.1,"institutionHeld":0,"latestPrice":4.2,"eps":-0.273692,"divideRate":0,"volume":64725,"delay":15,"ttmEps":-0.273692,"open":4.11,"prevYearClose":2.18,"prevWeekClose":4.28,"prevMonthClose":4.28,"prevQuarterClose":2.36,"fiveDayClose":4.28,"twentyDayClose":2.3,"sixtyDayClose":2.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGENF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-14","symbol":"NGENF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-08-22","symbol":"NGENF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1724299200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-16","symbol":"NGENF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715832000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2022-11-14","symbol":"NGENF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1668402000000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGENF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGENF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1750050000000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":577702483,"yearFounded":2017,"address":"112-970 Burrard Street,Unit 1290,Vancouver,British Columbia,Canada","zipCode":"V6Z 2R4","officePhone":"778-731-1711"},"stockCompanyDetail":{"websiteUrl":"https://www.nervgen.com","stockEarnings":[{"period":"1week","weight":-0.0917},{"period":"1month","weight":-0.0748},{"period":"3month","weight":-0.1162},{"period":"6month","weight":-0.1722},{"period":"ytd","weight":-0.1722}],"description":"NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.","exchange":"OTCQB","name":"NervGen Pharma Corp.","nameEN":"NervGen Pharma Corp."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NGENF\",market:\"US\",,,undefined,":null}}